Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,552.00-0.29%ETH$2,697.47-0.58%GOLD$4,187.80+0.02%OIL$90.23+0.88%
Smart Investors Daily
SID Premium
AK

NASDAQ · AKBA

Akebia Therapeutics, Inc.

Healthcare · Biotechnology

$0.91

Down-$0.03 (-3.51%)

Updated Oct 7, 2026, 12:03 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
347.63M
P/E ratio
-65.04
Dividend yield
0.00%
52-week range
$0.81 – $3.20
Volume
7.51M
Avg. volume
3.34M

Price performance · AKBA

AKBA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

AKBA closed at $0.91 after 20 trading sessions, down 11.60% for the selected period.

Last close
$0.91
Period change
-11.60%
Period low
$0.87
Period high
$1.03
Daily close
View OHLC price history
AKBA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$0.87$0.92$0.8451$0.91057.51M
Oct 2, 2026$0.888$0.8885$0.84$0.8657.11M
Oct 1, 2026$0.9149$0.9199$0.868$0.8714.52M
Sep 30, 2026$0.8939$0.9311$0.866$0.9210.83M
Sep 29, 2026$0.8996$0.90$0.87$0.88613.45M
Sep 28, 2026$0.8863$0.8999$0.875$0.89313.4M
Sep 25, 2026$0.9211$0.9269$0.8929$0.89624.38M
Sep 24, 2026$0.92$0.9482$0.9104$0.9193.73M
Sep 23, 2026$0.987$0.987$0.93$0.93265.39M
Sep 22, 2026$0.95$1.00$0.9395$0.985.11M
Sep 21, 2026$0.927$0.946$0.9178$0.938511.09M
Sep 18, 2026$0.89$0.9266$0.88$0.91577.37M
Sep 17, 2026$0.9256$0.9401$0.8702$0.89558.72M
Sep 16, 2026$0.9082$0.9362$0.8952$0.91787.5M
Sep 15, 2026$0.9617$0.977$0.9026$0.9035.78M
Sep 14, 2026$0.952$1.02$0.9026$0.96298.83M
Sep 11, 2026$0.97$0.9828$0.9512$0.95176.14M
Sep 10, 2026$0.95$0.9677$0.9312$0.94654.92M
Sep 9, 2026$1.03$1.049$0.95$0.95394.88M
Sep 8, 2026$0.9616$1.03$0.9528$1.033.06M

Latest AKBA news

The latest Smart Investors Daily articles mentioning AKBA.

Stock researchCompany · Overview

AKBA research

Overview

Company profile and research snapshot.

Company profile

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.50
Implied upside
—
Analysts
—
AKBA recent ratings
DateFirmRatingTarget
Sep 15, 2026BTIGBuy—
Sep 8, 2026WestPark CapitalBuy—
Aug 7, 2026Leerink PartnersMarket Perform—
Jul 1, 2026HC Wainwright & Co.Buy—
Apr 7, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industryJERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026. Dr. Burke brings more than 30 years of indu

Yahoo · Sep 14, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediat

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By